Skip CCR Main Navigation National Cancer Institute National Cancer Institute U.S. National Institutes of Health
CCR - For Our Staff| Home |

Our Science – Hakim Website

Frances T. Hakim, Ph.D.

Selected Publications

1)  Imanguli MM, Cowen EW, Rose J, Dhamala S, Swaim W, Lafond S, Yagi B, Gress RE, Pavletic SZ, Hakim FT.
Comparative analysis of FoxP3(+) regulatory T cells in the target tissues and blood in chronic graft versus host disease.
Leukemia. [Epub ahead of print], 2014.
2)  Kochenderfer JN, Dudley ME, Carpenter RO, Kassim SH, Rose JJ, Telford WG, Hakim FT, Halverson DC, Fowler DH, Hardy NM, Mato AR, Hickstein DD, Gea-Banacloche JC, Pavletic SZ, Sportes C, Maric I, Feldman SA, Hansen BG, Wilder JS, Blacklock-Schuver B, Jena B, Bishop MR, Gress RE, Rosenberg SA.
Donor-derived CD19-targeted T cells cause regression of malignancy persisting after allogeneic hematopoietic stem cell transplantation.
Blood. 122: 4129-39, 2013.
3)  Salit RB, Fowler DH, Dean RM, Pavletic SZ, Hakim FT, Steinberg SM, Hardy NT, Sportes C, Gress RE, Bishop MR.
Host lymphocyte depletion as a strategy to facilitate early full donor chimerism after reduced-intensity allogeneic stem cell transplantation.
Biol. Blood Marrow Transplant. 19: 1509-13, 2013.
4)  Carpenter RO, Evbuomwan MO, Pittaluga S, Rose JJ, Raffeld M, Yang S, Gress RE, Hakim FT, Kochenderfer JN.
B-cell Maturation Antigen Is a Promising Target for Adoptive T-cell Therapy of Multiple Myeloma.
Clin. Cancer Res. 19: 2048-60, 2013.
5)  Fowler DH, Mossoba ME, Steinberg SM, Halverson DC, Stroncek D, Khuu HM, Hakim FT, Castiello L, Sabatino M, Leitman SF, Mariotti J, Gea-Banacloche JC, Sportes C, Hardy NM, Hickstein DD, Pavletic SZ, Rowley S, Goy A, Donato M, Korngold R, Pecora A, Levine BL, June CH, Gress RE, Bishop MR.
Phase 2 clinical trial of rapamycin-resistant donor CD4+ Th2/Th1 (T-Rapa) cells after low-intensity allogeneic hematopoietic cell transplantation.
Blood. 121: 2864-74, 2013.
6)  Grkovic L, Baird K, Steinberg SM, Williams KM, Pulanic D, Cowen EW, Mitchell SA, Hakim FT, Martires KJ, Avila DN, Taylor TN, Salit RB, Rowley SD, Zhang D, Fowler DH, Bishop MR, Gress RE, Pavletic SZ.
Clinical laboratory markers of inflammation as determinants of chronic graft-versus-host disease activity and NIH global severity.
Leukemia. 26: 633-43, 2012.
7)  Hardy NM, Fellowes V, Rose JJ, Odom J, Pittaluga S, Steinberg SM, Blacklock-Schuver B, Avila DN, Memon S, Kurlander RJ, Khuu HM, Stetler-Stevenson M, Mena E, Dwyer AJ, Levine BL, June CH, Reshef R, Vonderheide RH, Gress RE, Fowler DH, Hakim FT, Bishop MR.
Costimulated tumor-infiltrating lymphocytes are a feasible and safe alternative donor cell therapy for relapse after allogeneic stem cell transplantation.
Blood. 119: 2956-9, 2012.
8)  Salit RB, Fowler DH, Wilson WH, Dean RM, Pavletic SZ, Dunleavy K, Hakim F, Fry TJ, Steinberg SM, Hughes TE, Odom J, Bryant K, Gress RE, Bishop MR.
Dose-adjusted EPOCH-rituximab combined with fludarabine provides an effective bridge to reduced-intensity allogeneic hematopoietic stem-cell transplantation in patients with lymphoid malignancies.
J. Clin. Oncol. 30: 830-6, 2012.
9)  Fassil H, Bassim CW, Mays J, Edwards D, Baird K, Steinberg SM, Williams KM, Cowen EW, Mitchell SA, Hakim FT, Taylor T, Avila D, Zhang D, Grkovic L, Datiles M, Gress RE, Pavletic SZ.
Oral chronic graft-vs.-host disease characterization using the NIH scale.
J. Dent. Res. 91: 45S-51S, 2012.
10)  Memon SA, Sportès C, Flomerfelt FA, Gress RE, Hakim FT.
Quantitative analysis of T cell receptor diversity in clinical samples of human peripheral blood.
J. Immunol. Methods. 375: 84-92, 2012.
11)  Hakim F.
CGVHD: Inflammation at the Crossroads of Allo and Auto Immunity. In: Signatures of Immune Rejection.
New York: Springer; 2011. p. 259-280 [Book Chapter]
12)  Jamshed S, Fowler DH, Neelapu SS, Dean RM, Steinberg SM, Odom J, Bryant K, Hakim F, Bishop MR.
EPOCH-F: a novel salvage regimen for multiple myeloma before reduced-intensity allogeneic hematopoietic SCT.
Bone Marrow Transplant. 46: 676-81, 2011.
13)  Le RQ, Melenhorst JJ, Battiwalla M, Hill B, Memon S, Savani BN, Shenoy A, Hensel NF, Koklanaris EK, Keyvanfar K, Hakim FT, Douek DC, Barrett AJ.
Evolution of the donor T-cell repertoire in recipients in the second decade after allogeneic stem cell transplantation.
Blood. 117: 5250-6, 2011.
14)  Martires KJ, Baird K, Citrin DE, Hakim FT, Pavletic SZ, Cowen EW.
Localization of sclerotic-type chronic graft-vs-host disease to sites of skin injury: potential insight into the mechanism of isomorphic and isotopic responses.
Arch Dermatol. 147: 1081-6, 2011.
15)  Hardy NM, Mossoba ME, Steinberg SM, Fellowes V, Yan XY, Hakim FT, Babb RR, Avila D, Gea-Banacloche J, Sportès C, Levine BL, June CH, Khuu HM, Carpenter AE, Krumlauf MC, Dwyer AJ, Gress RE, Fowler DH, Bishop MR.
Phase I trial of adoptive cell transfer with mixed-profile type-I/type-II allogeneic T cells for metastatic breast cancer.
Clin. Cancer Res. 17: 6878-87, 2011.
16)  Martires KJ, Baird K, Steinberg SM, Grkovic L, Joe GO, Williams KM, Mitchell SA, Datiles M, Hakim FT, Pavletic SZ, Cowen EW.
Sclerotic-type chronic GVHD of the skin: clinical risk factors, laboratory markers, and burden of disease.
Blood. 118: 4250-7, 2011.
17)  Sportès C, Babb RR, Krumlauf MC, Hakim FT, Steinberg SM, Chow CK, Brown MR, Fleisher TA, Noel P, Maric I, Stetler-Stevenson M, Engel J, Buffet R, Morre M, Amato RJ, Pecora A, Mackall CL, Gress RE.
Phase I study of recombinant human interleukin-7 administration in subjects with refractory malignancy.
Clin. Cancer Res. 16: 727-35, 2010.
18)  Imanguli MM, Atkinson JC, Mitchell SA, Avila DN, Bishop RJ, Cowen EW, Datiles MB, Hakim FT, Kleiner DE, Krumlauf MC, Pavletic SZ.
Salivary Gland Involvement by Chronic Graft-Versus-Host Disease: Prevalence, Clinical Significance and Recommendations for Evaluation.
Biol Blood Marrow Transplant. 16: 1362-1369, 2010.
19)  Lee DK, Hakim FT, Gress RE.
The thymus and the immune system: layered levels of control.
J Thorac Oncol. 5: S273-6, 2010.
20)  Sportes C, Hakim F.
Fulop T, Franceschi C, Hirokawa K, Pawelec G, eds.
Aging, immunity and cancer. In: Handbook of Immunosenescence. Volume 2.
New York: Springer; 2009. p. 1119-1138 [Book Chapter]
21)  Hakim F.
Fulop T, Franceschi C, Hirokawa K, Pawelec G, eds.
Thymic involution and renewal. In: Handbook of Immunosenescence. Volume I.
New York: Springer; 2009. p. 865-891 [Book Chapter]
22)  Olkhanud PB, Baatar D, Bodogai M, Hakim F, Gress R, Anderson RL, Deng J, Xu M, Briest S, Biragyn A.
Breast cancer lung metastasis requires expression of chemokine receptor CCR4 and regulatory T cells.
Cancer Res. 69: 5996-6004, 2009.
23)  Imanguli MM, Swaim WD, League SC, Gress RE, Pavletic SZ, Hakim FT.
Increased T-bet+ cytotoxic effectors and type I interferon-mediated processes in chronic graft-versus-host disease of the oral mucosa.
Blood. 113: 3620-30, 2009.
24)  Kapoor V, Hakim FT, Rehman N, Gress RE, Telford WG.
Quantum dots thermal stability improves simultaneous phenotype-specific telomere length measurement by FISH-flow cytometry.
J. Immunol. Methods. 344: 6-14, 2009.
25)  Hakim FT.
TRECing long-term success in SCID.
Blood. 114: 1287-8, 2009.
26)  Sportès C, Hakim FT, Memon SA, Zhang H, Chua KS, Brown MR, Fleisher TA, Krumlauf MC, Babb RR, Chow CK, Fry TJ, Engels J, Buffet R, Morre M, Amato RJ, Venzon DJ, Korngold R, Pecora A, Gress RE, Mackall CL.
Administration of rhIL-7 in humans increases in vivo TCR repertoire diversity by preferential expansion of naive T cell subsets.
J. Exp. Med. 205: 1701-14, 2008.
27)  Dean RM, Fry T, Mackall C, Steinberg SM, Hakim F, Fowler D, Odom J, Foley J, Gress R, Bishop MR.
Association of serum interleukin-7 levels with the development of acute graft-versus-host disease.
J. Clin. Oncol. 26: 5735-41, 2008.
28)  Boyiadzis M, Memon S, Carson J, Allen K, Szczepanski MJ, Vance BA, Dean R, Bishop MR, Gress RE, Hakim FT.
Up-regulation of NK cell activating receptors following allogeneic hematopoietic stem cell transplantation under a lymphodepleting reduced intensity regimen is associated with elevated IL-15 levels.
Biol. Blood Marrow Transplant. 14: 290-300, 2008.
29)  Hardy NM, Hakim F, Steinberg SM, Krumlauf M, Cvitkovic R, Babb R, Odom J, Fowler DH, Gress RE, Bishop MR.
Host T cells affect donor T cell engraftment and graft-versus-host disease after reduced-intensity hematopoietic stem cell transplantation.
Biol. Blood Marrow Transplant. 13: 1022-30, 2007.
30)  Hakim FT, Gress RE.
Immunosenescence: deficits in adaptive immunity in the elderly.
Tissue Antigens. 70: 179-89, 2007.
31)  Williams KM, Hakim FT, Gress RE.
T cell immune reconstitution following lymphodepletion.
Semin. Immunol. 19: 318-30, 2007.
32)  Hakim FT, Gress RE.
Thymic involution: implications for self-tolerance.
Methods Mol. Biol. 380: 377-90, 2007.
33)  Lucas PJ, Kim SJ, Mackall CL, Telford WG, Chu YW, Hakim FT, Gress RE.
Dysregulation of IL-15-mediated T-cell homeostasis in TGF-beta dominant-negative receptor transgenic mice.
Blood. 108: 2789-95, 2006.
34)  Hakim FT, Memon SA, Cepeda R, Jones EC, Chow CK, Kasten-Sportes C, Odom J, Vance BA, Christensen BL, Mackall CL, Gress RE.
Age-dependent incidence, time course, and consequences of thymic renewal in adults.
J. Clin. Invest. 115: 930-9, 2005.
35)  Hakim FT, Gress RE.
Reconstitution of the lymphocyte compartment after lymphocyte depletion: a key issue in clinical immunology.
Eur. J. Immunol. 35: 3099-102, 2005.
36)  Muraro PA, Douek DC, Packer A, Chung K, Guenaga FJ, Cassiani-Ingoni R, Campbell C, Memon S, Nagle JW, Hakim FT, Gress RE, McFarland HF, Burt RK, Martin R.
Thymic output generates a new and diverse TCR repertoire after autologous stem cell transplantation in multiple sclerosis patients.
J. Exp. Med. 201: 805-16, 2005.
37)  Hakim FT, Flomerfelt FA, Boyiadzis M, Gress RE.
Aging, immunity and cancer.
Curr. Opin. Immunol. 16: 151-6, 2004.
38)  Chu YW, Memon SA, Sharrow SO, Hakim FT, Eckhaus M, Lucas PJ, Gress RE.
Exogenous IL-7 increases recent thymic emigrants in peripheral lymphoid tissue without enhanced thymic function.
Blood. 104: 1110-9, 2004.
39)  Yamashita K, Choi U, Woltz PC, Foster SF, Sneller MC, Hakim FT, Fowler DH, Bishop MR, Pavletic SZ, Tamari M, Castro K, Barrett AJ, Childs RW, Illei GG, Leitman SF, Malech HL, Horwitz ME.
Severe chronic graft-versus-host disease is characterized by a preponderance of CD4(+) effector memory cells relative to central memory cells.
Blood. 103: 3986-8, 2004.
40)  Hakim FT, Gress RE.
Reconstitution of thymic function after stem cell transplantation in humans.
Curr. Opin. Hematol. 9: 490-6, 2002.
41)  Zujewski J, Horak ID, Bol CJ, Woestenborghs R, Bowden C, End DW, Piotrovsky VK, Chiao J, Belly RT, Todd A, Kopp WC, Kohler DR, Chow C, Noone M, Hakim FT, Larkin G, Gress RE, Nussenblatt RB, Kremer AB, Cowan KH.
Phase I and pharmacokinetic study of farnesyl protein transferase inhibitor R115777 in advanced cancer.
J. Clin. Oncol. 18: 927-41, 2000.
42)  Mackall CL, Stein D, Fleisher TA, Brown MR, Hakim FT, Bare CV, Leitman SF, Read EJ, Carter CS, Wexler LH, Gress RE.
Prolonged CD4 depletion after sequential autologous peripheral blood progenitor cell infusions in children and young adults.
Blood. 96: 754-62, 2000.
Click Here to View Collapsed Bibliography.

This page was last updated on 4/9/2014.